These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19486955)

  • 1. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
    Kaltenböck A; Dubischar-Kastner K; Eder G; Jilg W; Klade C; Kollaritsch H; Paulke-Korinek M; von Sonnenburg F; Spruth M; Tauber E; Wiedermann U; Schuller E
    Vaccine; 2009 Jul; 27(33):4483-9. PubMed ID: 19486955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.
    Schuller E; Klade CS; Wölfl G; Kaltenböck A; Dewasthaly S; Tauber E
    Vaccine; 2009 Mar; 27(15):2188-93. PubMed ID: 19200452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial.
    Jiang WP; Chen JT; Wang X; Wang YL; Liu Y; Chen WY; Xu WG; Qiu YZ; Yin WD
    Vaccine; 2008 Apr; 26(18):2297-301. PubMed ID: 18395305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
    Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.
    Kaltenböck A; Dubischar-Kastner K; Schuller E; Datla M; Klade CS; Kishore TS
    Vaccine; 2010 Jan; 28(3):834-9. PubMed ID: 19857447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the immunogenicity and safety of 2 kinds of inactivated hepatitis A vaccine vaccinated in 1-3 years old children].
    Fu Y; Li ZL; Lao SJ; Wang M; Chen QB; Chen SJ; Li JG; Zhang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):551-2. PubMed ID: 15231151
    [No Abstract]   [Full Text] [Related]  

  • 11. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
    Lyons A; Kanesa-thasan N; Kuschner RA; Eckels KH; Putnak R; Sun W; Burge R; Towle AC; Wilson P; Tauber E; Vaughn DW
    Vaccine; 2007 Apr; 25(17):3445-53. PubMed ID: 17241714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
    Zheng H; Chen Y; Wang F; Gong X; Wu Z; Miao N; Zhang X; Li H; Chen C; Hou X; Cui F; Wang H
    Vaccine; 2011 Nov; 29(48):9098-103. PubMed ID: 21875638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.
    Wallace MR; Brandt CJ; Earhart KC; Kuter BJ; Grosso AD; Lakkis H; Tasker SA
    Clin Infect Dis; 2004 Oct; 39(8):1207-13. PubMed ID: 15486846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.
    Torresi J; McCarthy K; Feroldi E; Méric C
    Vaccine; 2010 Nov; 28(50):7993-8000. PubMed ID: 20934459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children].
    Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.